Emerging drugs for the treatment of hypercholesterolemia.

Emerging drugs for the treatment of hypercholesterolemia. Expert Opin Emerg Drugs. 2019 Mar 06;: Authors: Bove M, Cicero AFG, Borghi C Abstract Introduction Despite the consolidated role of statins and ezetimibe to treat hypercholesterolemia, often the desirable Low-Density-Lipoprotein-cholesterol (LDL-C) values are not achieved, with a consequent increase of the residual cardiovascular (CV) risk. Areas covered In this review, we summarize the main pharmacological characteristics of new lipid-lowering drugs, such as Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors, Cholesteryl-Ester-Transfer Protein inhibitors, Microsomal Triglyceride Transfer Protein inhibitors, ATP citrate lyase inhibitors, Antisense Oligonucleotides, small interfering RNA and Peroxisome Proliferator-Activated Receptors type α agonists. The available clinical evidence of efficacy and safety is critically discussed as well as the prospects of application, based on the different mechanisms and targets of action. Expert opinion Some of these emerging agents represent an excellent therapeutic strategy to treat patients with LDL largely out of target, resistant or intolerant to statins, trying to minimize the residual CV risk, modulating different classes of lipoproteins, not just LDL. The main challenge for the large use of emerging drugs is their cost. Thus, the correct identification of the adequate target population for treatment is a priority. This...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research